News

Johnson & Johnson is recalling 70,000 syringes preloaded with its Invega injectable anti-psychotic drug, the WSJ reports. Cracks have been found in the syringes that could theoretically lead to ...
NEW YORK (AP) - A unit of Johnson & Johnson has recalled 70,000 syringes of its antipsychotic drug Invega Sustenna after finding that some of the pre-filled syringes may have cracks which possibly ...
Johnson & Johnson recalled about 70,000 syringes of the antipsychotic drug Invega after finding cracks in the syringes, which could cause infections or reduced efficacy in users, the Wall Street ...
A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ) in a patent dispute with Viatris (NASDAQ:VTRS) and Teva ...
Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to ...
Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and ...
In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
As previously reported, the Federal Court released a pair of decisions relating to paliperidone palmitate (Janssen’s INVEGA SUSTENNA), finding in a summary trial that each of Pharmascience and ...
J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report.
Meanwhile, Darzalex, a multiple myeloma drug JNJ markets with Genmab , brought $2.9B to the top line, while antipsychotic Invega Sustenna generated $1.1B with ~18% YoY and ~2% YoY growth ...
J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report.